Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26262
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBucci, Marco-
dc.contributor.authorSavitcheva, Irina-
dc.contributor.authorFarrar, Gill-
dc.contributor.authorSalvadó, Gemma-
dc.contributor.authorCollij, Lyduine-
dc.contributor.authorDoré, Vincent-
dc.contributor.authorGispert, Juan Domingo-
dc.contributor.authorGunn, Roger-
dc.contributor.authorHanseeuw, Bernard-
dc.contributor.authorHansson, Oskar-
dc.contributor.authorShekari, Mahnaz-
dc.contributor.authorLhommel, Renaud-
dc.contributor.authorMolinuevo, José Luis-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorSur, Cyrille-
dc.contributor.authorWhittington, Alex-
dc.contributor.authorBuckley, Christopher-
dc.contributor.authorNordberg, Agneta-
dc.date2021-04-12-
dc.date.accessioned2021-04-19T05:58:53Z-
dc.date.available2021-04-19T05:58:53Z-
dc.date.issued2021-07-
dc.identifier.citationEuropean Journal of Nuclear Medicine and Molecular Imaging 2021; 48(7): 2183-2199en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/26262-
dc.description.abstract[18F]flutemetamol PET scanning provides information on brain amyloid load and has been approved for routine clinical use based upon visual interpretation as either negative (equating to none or sparse amyloid plaques) or amyloid positive (equating to moderate or frequent plaques). Quantitation is however fundamental to the practice of nuclear medicine and hence can be used to supplement amyloid reading methodology especially in unclear cases. A total of 2770 [18F]flutemetamol images were collected from 3 clinical studies and 6 research cohorts with available visual reading of [18F]flutemetamol and quantitative analysis of images. These were assessed further to examine both the discordance and concordance between visual and quantitative imaging primarily using thresholds robustly established using pathology as the standard of truth. Scans covered a wide range of cases (i.e. from cognitively unimpaired subjects to patients attending the memory clinics). Methods of quantifying amyloid ranged from using CE/510K cleared marked software (e.g. CortexID, Brass), to other research-based methods (e.g. PMOD, CapAIBL). Additionally, the clinical follow-up of two types of discordance between visual and quantitation (V+Q- and V-Q+) was examined with competing risk regression analysis to assess possible differences in prediction for progression to Alzheimer's disease (AD) and other diagnoses (OD). Weighted mean concordance between visual and quantitation using the autopsy-derived threshold was 94% using pons as the reference region. Concordance from a sensitivity analysis which assessed the maximum agreement for each cohort using a range of cut-off values was also estimated at approximately 96% (weighted mean). Agreement was generally higher in clinical cases compared to research cases. V-Q+ discordant cases were 11% more likely to progress to AD than V+Q- for the SUVr with pons as reference region. Quantitation of amyloid PET shows a high agreement vs binary visual reading and also allows for a continuous measure that, in conjunction with possible discordant analysis, could be used in the future to identify possible earlier pathological deposition as well as monitor disease progression and treatment effectiveness.en
dc.language.isoeng-
dc.subjectAlzheimer’s diseaseen
dc.subjectAmyloid PETen
dc.subjectImage interpretationen
dc.subjectQuantificationen
dc.subjectVisual inspectionen
dc.subject[18F]flutemetamolen
dc.titleA multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images.en
dc.typeJournal Articleen
dc.identifier.journaltitleEuropean Journal of Nuclear Medicine and Molecular Imagingen
dc.identifier.affiliationDepartment of Aging, Karolinska University Hospital, Stockholm, Swedenen
dc.identifier.affiliationDivision of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.en
dc.identifier.affiliationDivision of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Swedenen
dc.identifier.affiliationPharmaceutical Diagnostics, GE Healthcare, Amersham, UKen
dc.identifier.affiliationDivision of Brain Sciences, Department of Medicine, Imperial College, London, UKen
dc.identifier.affiliationUniversity of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationIMIM (Hospital del Mar Medical Research Institute), Barcelona, Spainen
dc.identifier.affiliationInvicro, London, UKen
dc.identifier.affiliationNeurology and Nuclear Medicine Departments, Saint-Luc University Hospital, Av. Hippocrate, 10, 1200, Brussels, Belgiumen
dc.identifier.affiliationGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USAen
dc.identifier.affiliationBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spainen
dc.identifier.affiliationIMIM (Hospital del Mar Medical Research Institute), Barcelona, Spainen
dc.identifier.affiliationUniversitat Pompeu Fabra, Barcelona, Spainen
dc.identifier.affiliationCentro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spainen
dc.identifier.affiliationUniversitat Pompeu Fabra, Barcelona, Spainen
dc.identifier.affiliationInvicro, London, UKen
dc.identifier.affiliationCentro de Investigación Biomédica en Red Bioingenieriá, Biomateriales y Nanomedicina, (CIBER-BBN), Barcelona, Spainen
dc.identifier.affiliationMedical Radiation Physics and Nuclear Medicine, Section for Nuclear Medicine, Karolinska University Hospital, Stockholm, Swedenen
dc.identifier.affiliationDepartment of Medicine, The University of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationHealth and Biosecurity, CSIRO, Parkville, Australiaen
dc.identifier.affiliationMerck & Co., Inc., Kenilworth, NJ, USAen
dc.identifier.affiliationDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117, Amsterdam, Netherlandsen
dc.identifier.affiliationClinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Lund, Swedenen
dc.identifier.affiliationNeurology and Nuclear Medicine Departments, Saint-Luc University Hospital, Av. Hippocrate, 10, 1200, Brussels, Belgiumen
dc.identifier.affiliationMolecular Imaging and Therapyen
dc.identifier.doi10.1007/s00259-021-05311-5en
dc.type.contentTexten
dc.identifier.orcid0000-0001-7345-5151en
dc.identifier.pubmedid33844055-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Jul 2, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.